Drug combo for colorectal cancer that cannot be removed yet
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (FOLFOX chemotherapy, fruquintinib, and serplulimab) as a first treatment for people with a specific type of colorectal cancer that cannot be surgically removed. The goal is to shrink the cancer enough to make surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your colorectal cancer is locally advanced or has spread, and cannot be surgically removed at this time
- You have not had any prior chemotherapy or other systemic treatment for your colorectal cancer
- Your tumor is pMMR (or MSS/MSI-L) – a type that does not have high microsatellite instability
- You are in fairly good health, able to do light activities, and have normal organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—fruquintinib (an anti-angiogenic agent), serplulimab (an immune-boosting antibody), and standard chemotherapy—as a first-line treatment for advanced colorectal cancer with specific genetic mutations. The goal is to see if this combination can help shrink or control tumors better than standard treatment alone.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests a combination of two oral drugs (fruquintinib and camrelizumab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with advanced colorectal cancer that has spread to the liver. It's for those whose first treatment has stopped working and whose cancer is not the MSI-H type.
This trial tests a combination of three new drugs (S-531011, fruquintinib, and possibly pembrolizumab) to treat advanced colorectal cancer that has spread and stopped responding to standard chemotherapy. The trial is designed to see if this combination is safe and effective for patients whose tumors have a specific genetic profile.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.